This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial (KITS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2011 by Ban Tsui, University of Alberta.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Ban Tsui, University of Alberta Identifier:
First received: December 21, 2011
Last updated: December 22, 2011
Last verified: December 2011
Our group wishes to test the novel hypothesis that intraoperative use of ketorolac in pediatric patients undergoing tonsillectomy reduces post-operative nausea and vomiting, postoperative pain scores, subsequent narcotic use, and length of hospital stay without adversely affecting post-operative bleed risk, when compared to placebo, in a double-blind, randomized controlled trial.

Condition Intervention
Recurrent Acute Tonsillitis Drug: Ketorolac Drug: Normal Saline

Study Type: Interventional
Official Title: KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial

Resource links provided by NLM:

Further study details as provided by Ban Tsui, University of Alberta:

Primary Outcome Measures:
  • Pain

Arms Assigned Interventions
Experimental: Ketorolac Drug: Ketorolac
Placebo Comparator: Placebo Drug: Normal Saline

  Show Detailed Description


Ages Eligible for Study:   3 Years to 15 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients aged 3yrs-15yrs who will undergo tonsillectomy or adeno-tonsillectomy for sleep disordered breathing confirmed by oximetry

Exclusion Criteria:

  • Severe Obstructive Sleep Apnea
  • Co-morbid disease precluding use of NSAIDS or Narcotics
  • Language/developmental/social inability to assess pain scores
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01498796

Canada, Alberta
Stollery Children's Hospital Recruiting
Edmonton, Alberta, Canada, T6G 2B7
Contact: Eduard Eksteen, MD    780.407.2109    Eduard Eksteen <>   
Sub-Investigator: Morgan A Langille, MD         
Sub-Investigator: David WJ Cote, MD         
Sub-Investigator: Trina Uwiera, MD         
Sub-Investigator: Paula Holinski, MD         
Principal Investigator: Eduard Eksteen, MD         
Principal Investigator: Ban Tsui, MD         
Sponsors and Collaborators
University of Alberta
  More Information

Responsible Party: Ban Tsui, MD, University of Alberta Identifier: NCT01498796     History of Changes
Other Study ID Numbers: Pro00002357
Study First Received: December 21, 2011
Last Updated: December 22, 2011

Additional relevant MeSH terms:
Pharyngeal Diseases
Stomatognathic Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Ketorolac Tromethamine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017